PEDF-derived peptide inhibits corneal angiogenesis by suppressing VEGF expression

Microvascular Research

Volumn 84, Issue 1, 2012, Pages 105-108

  Matsui, Takanori ^a   Nishino, Yuri ^a   Maeda, Sayaka ^a   Yamagishi, Sho ichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; P5-1 PEPTIDE; P5-2 PEPTIDE; P5-3 PEPTIDE; PHOSPHATE BUFFERED SALINE; PIGMENT EPITHELIUM DERIVED FACTOR; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA INJURY; CORNEA NEOVASCULARIZATION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; IN VIVO STUDY; MALE; MOLECULAR MODEL; MOLECULAR WEIGHT; NONHUMAN; OXIDATIVE STRESS; PEPTIDE ANALYSIS; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RESIDUE ANALYSIS;

ADMINISTRATION, TOPICAL; ANGIOGENESIS INHIBITORS; ANIMALS; CAUTERY; CORNEA; CORNEAL NEOVASCULARIZATION; DEOXYGUANOSINE; DISEASE MODELS, ANIMAL; EYE PROTEINS; MALE; NERVE GROWTH FACTORS; RATS; RATS, SPRAGUE-DAWLEY; SERPINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MAMMALIA; RATTUS;

EID: 84861530783     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2012.02.006     Document Type: Article

References (22)

1. Abe R., Yamagishi S., Fujita Y., Hoshina D., Sasaki M., Nakamura K., Matsui T., Shimizu T., Bucala R., Shimizu H. Topical application of anti-angiogenic peptides based on pigment epithelium-derived factor can improve psoriasis. J. Dermatol. Sci. 2010, 57:183-191.
2. Bachmann B., Taylor R.S., Cursiefen C. The association between corneal neovascularization and visual acuity: a systematic review. Acta Ophthalmol 2011, 10.1111/j.1755-3768.2011.02312.x.
3. Becerra E.M., Morescalchi F., Gandolfo F., Danzi P., Nascimbeni G., Arcidiacono B., Semeraro F. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration. Curr. Drug Targets. 2011, 12:149-172.
4. Cursiefen C., Colin J., Dana R., Diaz-Llopis M., Faraj L.A., Garcia-Delpech S., Geerling G., Price F.W., Remeijer L., Rouse B.T., Seitz B., Udaondo P., Meller D., Dua H. Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable. Br. J. Ophthalmol. 2012, 96:3-9.
5. Dan L., Shi-long Y., Miao-li L., Yong-ping L., Hong-jie M., Ying Z., Xiang-gui W. Inhibitory effect of oral doxycycline on neovascularization in a rat corneal alkali burn model of angiogenesis. Curr. Eye Res. 2008, 33:653-660.
6. Dawson D.W., Volpert O.V., Gillis P., Crawford S.E., Xu H.J., Benedict W., Bouck N.P. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science 1999, 285:245-248.
7. Duh E.J., Yang H.S., Suzuma I., Miyagi M., Youngman E., Mori K., Katai M., Yan L., Suzuma K., West K., Davarya S., Tong P., Gehlbach P., Pearlman J., Crabb J.W., Aiello L.P., Campochiaro P.A., Zack D.J. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest. Ophthalmol. Vis. Sci. 2002, 43:821-829.
8. Ek E.T., Dass C.R., Contreras K.G., Choong P.F. PEDF-derived synthetic peptides exhibit antitumor activity in an orthotopic model of human osteosarcoma. J. Orthop. Res. 2007, 25:1671-1680.
9. Jin J., Ma J.X., Guan M., Yao K. Inhibition of chemical cautery-induced corneal neovascularization by topical pigment epithelium-derived factor eyedrops. Cornea 2010, 29:1055-1061.
10. Kawaguchi T., Yamagishi S.I., Sata M. Structure-function relationships of PEDF. Curr. Mol. Med. 2010, 10:302-311.
11. Kubota M., Shimmura S., Kubota S., Miyashita H., Kato N., Noda K., Ozawa Y., Usui T., Ishida S., Umezawa K., Kurihara T., Tsubota K. Hydrogen and N-acetyl-L-cysteine rescue oxidative stress-induced angiogenesis in a mouse corneal alkali-burn model. Invest. Ophthalmol. Vis. Sci. 2011, 52:427-433.
12. Riazi-Esfahani M., Peyman G.A., Aydin E., Kazi A.A., Kivilcim M., Sanders D.R. Prevention of corneal neovascularization: evaluation of various commercially available compounds in an experimental rat model. Cornea 2006, 25:801-805.
13. Scroggs M.W., Proia A.D., Smith C.F., Halperin E.C., Klintworth G.K. The effect of total-body irradiation on corneal neovascularization in the Fischer 344 rat after chemical cauterization. Invest. Ophthalmol. Vis. Sci. 1991, 32:2105-2111.
14. Spranger J., Osterhoff M., Reimann M., Möhlig M., Ristow M., Francis M.K., Cristofalo V., Hammes H.P., Smith G., Boulton M., Pfeiffer A.F. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 2001, 50:2641-2645.
15. Tombran-Tink J., Barnstable C.J. PEDF: a multifaceted neurotrophic factor. Nat. Rev. Neurosci. 2003, 4:628-636.
16. Tombran-Tink J., Chader C.G., Johnson L.V. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp. Eye Res. 1991, 53:411-414.
17. Yamagishi S., Inagaki Y., Amano S., Okamoto T., Takeuchi M., Makita Z. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem. Biophys. Res. Commun. 2002, 296:877-882.
18. Yamagishi S., Nakamura K., Matsui T., Inagaki Y., Takenaka K., Jinnouchi Y., Yoshida Y., Matsuura T., Narama I., Motomiya Y., Takeuchi M., Inoue H., Yoshimura A., Bucala R., Imaizumi T. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J. Biol. Chem. 2006, 281:20213-20220.
19. Yamagishi S.I., Nakamura K., Matsui T., Yoshida T., Takeuchi M., Imaizumi T. Pigment epithelium-derived factor (PEDF) blocks advanced glycation end product (AGE)-induced angiogenesis in vitro. Horm. Metab. Res. 2007, 39:233-235.
20. Yamagishi S., Matsui T., Nakamura K., Ueda S., Noda Y., Imaizumi T. Pigment epithelium-derived factor (PEDF): its potential therapeutic implication in diabetic vascular complications. Curr. Drug Targets. 2008, 9:1025-1029.
21. Yamagishi S., Matsui T., Nakamura K. Atheroprotective properties of pigment epithelium-derived factor (PEDF) in cardiometabolic disorders. Curr. Pharm. Des. 2009, 15:1027-1033.
22. Yokoi M., Yamagishi S., Saito A., Yoshida Y., Matsui T., Saito W., Hirose S., Ohgami K., Kase M., Ohno S. Positive association of pigment epithelium-derived factor with total antioxidant capacity in the vitreous fluid of patients with proliferative diabetic retinopathy. Br. J. Ophthalmol. 2007, 91:885-887.